Vantia Therapeutics’ Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
emerging pharmaceutical company developing novel, small molecule drugs
targeting large, underserved medical markets, announces positive results from
a Phase IIa clinical trial of its lead development compound VA106483 for
nocturia. The trial showed that oral VA106483 was successful in producing a
predictable and sustained anti-diuretic effect in patients, as determined by
increased osmolality and decreased urine output. The study also found that
VA106483 was generally well tolerated among the patient population.
Nocturia (defined as waking frequently to urinate at night thereby
disturbing sleep significantly) is a common condition, with prevalence
increasing markedly with age. It is often the presenting symptom in men with
benign prostatic hypertrophy (BPH) and affects at least 70% of BPH patients.
There is currently no adequate treatment for nocturia and it represents a
potential market estimated at more than
VA106483 is a novel small molecule drug candidate that exerts its effect
directly in the kidney by binding to vasopressin (V2) receptors, which
regulate water balance. It was discovered by Vantia from its extensive drug
candidate library.
The double-blind, placebo-controlled, dose-response study was designed to
investigate the pharmacodynamics and pharmacokinetics of single and repeated
oral doses of VA106483. The trial involved 27 elderly men aged 65 years or
more with a history of nocturia.
Based on these results, Vantia now plans to advance VA106483 into a
larger Phase IIb clinical efficacy study in the second half of 2009.
Dr
discovered and has been developed by Vantia based on its small molecule drug
development expertise and is the first of several potentially high-value drug
candidates in our pipeline. The clinical results for VA106483 are very
encouraging and we look forward to advancing it into the next stages of
clinical development. These results will also further highlight the value of
this new drug candidate as we progress partnership discussions in parallel. ‘
Notes to Editors:
About Vantia Therapeutics
Vantia Therapeutics is an emerging pharmaceutical company developing
novel, small molecule drugs targeting large, underserved medical markets.
Formed in 2008 as a spin-out of Ferring Research Ltd’s small molecule R&D, it
has two clinical phase products, VA106483 for the treatment of nocturia in
BPH patients and VA111913 for the treatment of dysmenorrhoea, as well as
preclinical and discovery programmes based on protease inhibition with
potential in the areas of oncology and inflammation. The company’s investors
include MVM Life Science Partners, SV Life Sciences and Novo A/S. Vantia
Therapeutics is situated on Southampton Science Park, UK, where it occupies
10,000 sq ft of chemistry and biology facilities. For further information,
please go to http://www.vantiatherapeutics.com.
About nocturia
Nocturia (defined as waking to void at night) is a common condition, with
prevalence increasing markedly with age. It is often the presenting symptom
of benign prostatic hypertrophy (BPH) with at least 70% of BPH patients
complaining of nocturia. Whilst some symptoms of BPH are successfully
addressed by the standard BPH therapies of alpha blockers and 5-alpha
reductase inhibitors, nocturia remains inadequately treated. With estimates
putting the number of BPH/nocturia sufferers at 55 million in the seven
largest markets world wide, and only 10% of these believed to be receiving
any kind of treatment, it is a clear area of unmet medical need estimated to
be worth in excess of
regulation of the body’s water content and as a vasopressin agonist VA106483
has been shown to act as an anti-diuretic.
Contact details:
Vantia Therapeutics
Dr Jim Phillips, CEO, +44(0)238-076-3433
info@vantia.com, +44(0)7515-397176
Citigate Dewe Rogerson
Chris Gardner, Mark Swallow, Helena Galilee, +44(0)207-638-9571
vantia@citigatedr.co.uk
SOURCE Vantia Therapeutics